73 Results for "

platelet function

" in MedChemExpress (MCE) Product Catalog:
Products (73)

73 Results for "platelet function" in MCE Product Catalog:

Cat. No.: HY-N6043R
CAS No.: 69039-02-7
Hydroxytyrosol acetate (Standard) is the analytical standard of Hydroxytyrosol (HY-N0570). This product is intended for research and analytical applications. Hydroxytyrosol acetate is an orally active, blood-brain barrier-permeable multi-active compound with multiple effects including antibacterial, antioxidant, anti-platelet aggregation, and neuroprotective activities. Hydroxytyrosol acetate not only inhibits the growth of Vibrio by increasing bacterial membrane permeability, but also interacts with DNA and mediates supercoiled DNA relaxation. Meanwhile, Hydroxytyrosol acetate effectively reduces thrombosis and inhibits lipid oxidation by inhibiting COX activity and promoting vascular nitric oxide production. In terms of neuroprotection, Hydroxytyrosol acetate significantly alleviates neuronal apoptosis and inflammatory responses by up-regulating the expression level of ERβ, thereby improving cognitive function in Alzheimer's disease models. Hydroxytyrosol acetate has been widely used in scientific research related to Vibrio infection, arterial thrombosis, Alzheimer's disease and other related fields .
loading...
    loading...
Cat. No.: HY-189107
CAS No.: 787548-03-2
Synonyms: INS50589 free acid
Target:  

P2Y Receptor

Research Areas:  

Cardiovascular Disease

Regrelor (INS50589 (free acid)) is a selective, reversible, and competitive P2Y12 receptor antagonist and an adenosine 5′-monophosphate derivative. Regrelor inhibits ADP (HY-W010918)-induced aggregation of human washed platelets with an IC50 of 0.016 μM. Intravenous infusion of Regrelor rapidly and dose-dependently inhibits ADP-induced platelet function, and platelet function gradually recovers after cessation of infusion. Regrelor can be used for research on P2Y12-mediated platelet function and cardiovascular regulation .
loading...
    loading...
Cat. No.: HY-W714099
CAS No.: 99103-16-9
U 66985 is a platelet-activating factor (PAF) receptor antagonist. U 66985 binds to the PAF receptor site, thereby inhibiting PAF-induced platelet aggregation. U 66985 can be used in studies on the PAF signaling pathway and the functions of lipid inflammatory mediators .
loading...
    loading...
Cat. No.: HY-179302
CAS No.: 104260-74-4
Research Areas:  

Cardiovascular Disease

SD3A is an antiplatelet agent. SD3A inhibits granule secretion and GP IIb/IIIa activation. SD3A inhibits mitochondrial function. SD3A has an antiaggregant effect on washed platelets stimulated with Collagen. SD3A results in reduced thrombus formation without affecting coagulation .
loading...
    loading...
Cat. No.: HY-122211
CAS No.: 1047980-53-9
Target:  

Endogenous Metabolite

Research Areas:  

Cardiovascular Disease

MRS2802 is a P2Y14 receptor agonist with an EC50 value of 63 nM. MRS2802 can effectively activate the P2Y14 receptor and may play a role in regulating platelet function. The selectivity and activity of MRS2802 are conducive to in-depth research on the biological functions and pharmacological properties of P2Y receptors. The development of MRS2802 provides a potential inhibitory strategy for the search for new antiplatelet compounds .
loading...
    loading...
Cat. No.: HY-L193
1,006 compounds

Since ancient times, promoting blood circulation for removing blood stasis (PBCRBS) has been one of the most popular research contents in the area of traditional Chinese medicine (TCM) and integrated medicine. Rhizoma, Persicae Semen, Carthami Flos, Curcumae Longae Rhizoma and so on are common TCM with PBCRBS characteristic. Studies have shown that the mechanism of action of PBCRBS TCM is to promote blood circulation (improving cardiovascular and cerebrovascular functions, physical and chemical properties of blood, platelet and coagulation system and other physiological functions) and remove blood stasis (anti-myocardial ischemia, cerebral ischemia, inhibition of platelet aggregation, anti-coagulation, anti-thrombosis, etc.). Not only that, PBCRBS TCM has anti-infection, inhibit inflammation, regulate immune function, inhibit immune response, inhibit abnormal tissue proliferation and other functions. Therefore, PBCRBS TCM has high research value in all- field disease research fields.

MCE can supply 1,006 monomer component from more than a hundred sources of PBCRBS TCM, which can be used in TCM studies, drug development and mechanism-based studies.

Cat. No.: HY-182573
CAS No.: 315203-31-7
RWJ-58259 is a selective PAR-1 inhibitor with an IC50 value of 0.15 μM. RWJ-58259 binds selectively to PAR-1, blocks the binding of tethered ligands, interferes with calcium mobilization and PAR-1-related cellular functions, and exhibits no PAR-1 agonist activity or thrombin proteolytic inhibitory activity. RWJ-58259 inhibits thrombin-induced platelet aggregation, calcium signaling and vascular smooth muscle cell proliferation, reduces neointimal thickness and arterial stenosis, and alleviates vascular occlusion and platelet deposition. RWJ-58259 can be used in the research of thrombotic diseases and vascular injury associated with acute coronary intervention .
loading...
    loading...
Cat. No.: HY-N18471
CAS No.: 31363-74-3
Synonyms: 5,7-DHP
5,7-Dihydroxytryptamine (5,7-DHP) is an autofluorescent (λex≈365 nm), selective neurotoxin and a transport substrate for MAO-A and 5-HT. 5,7-Dihydroxytryptamine can specifically target and damage central and peripheral 5-HTergic neurons, while affecting 5-HT-related pathways and neurotransmitter balance. 5,7-Dihydroxytryptamine can be used to establish 5-HTergic neuron injury models for studies on neural development, neurodegenerative diseases, as well as mechanisms related to platelet function and retinal neurons .
loading...
    loading...
Cat. No.: HY-N18471A
CAS No.: 1841081-30-8
Synonyms: 5,7-DHP hydrobromide
Research Areas:  

Neurological Disease

5,7-Dihydroxytryptamine (5,7-DHT) hydrobromide is an autofluorescent (Ex ≈ 365 nm), selective neurotoxin and a transport substrate for MAO-A and 5-HT. 5,7-Dihydroxytryptamine hydrobromide can specifically target and damage central and peripheral 5-HTergic neurons, while affecting 5-HT-related pathways and neurotransmitter balance. 5,7-Dihydroxytryptamine hydrobromide can be used to establish 5-HTergic neuron injury models for studies on neural development, neurodegenerative diseases, as well as mechanisms related to platelet function and retinal neurons .
loading...
    loading...
Cat. No.: HY-N18471B
CAS No.: 39929-27-6
Synonyms: 5,7-DHP creatinine sulfate
5,7-Dihydroxytryptamine creatinine sulfate (5,7-DHT) is an autofluorescent (Ex ≈ 365 nm), selective neurotoxin and a transport substrate for MAO-A and 5-HT. 5,7-Dihydroxytryptamine creatinine sulfate can specifically target and damage central and peripheral 5-HTergic neurons, while affecting 5-HT-related pathways and neurotransmitter balance. 5,7-Dihydroxytryptamine creatinine sulfate can be used to establish 5-HTergic neuron injury models for studies on neural development, neurodegenerative diseases, as well as mechanisms related to platelet function and retinal neurons .
loading...
    loading...
Cat. No.: HY-P11467
Gy-CATH is an anionic antimicrobial peptide. Gy-CATH activates MAPK and NF-κB signaling pathways (elevated levels of phospho-ERK, -p38, -JNK, -p65, and -IκBα). Gy-CATH upregulates the expression levels of three physiological anticoagulant pathways. Gy-CATH inhibits ADP-, Collagen-, and PMA-induced platelet aggregation. Gy-CATH has no direct antimicrobial activity, but shows significant preventive abilities against mice infected with Staphylococcus aureus, Escherichia coli, and Methicillin (HY-121544)-resistant Staphylococcus aureus. Gy-CATH exhibits potent immunomodulatory activity, enhancing macrophage-and neutrophil-mediated bactericidal functions. Gy-CATH significantly reduces the extent of pulmonary fibrin deposition and prevents thrombosis in mice .
loading...
    loading...
Cat. No.: HY-W751362
CAS No.: 14176-10-4
Cetiedil is a vasodilator and potassium channel blocker with anti-sickle cell and analgesic activities. Cetiedil increases cyclic adenosine monophosphate levels, relaxes vascular smooth muscle, and blocks the action of Bradykinin (HY-P0206). Cetiedil inhibits platelet aggregation, reduces plasma fibrinogen concentration and blood viscosity, suppresses sickling of sickle red blood cells and improves their filterability, and decreases irreversible sickle cells. Cetiedil binds to calmodulin, inhibits Ca 2+-dependent potassium permeability of erythrocyte membranes, increases sodium permeability of erythrocytes, and regulates polymorphonuclear leukocyte function. Cetiedil can be used in research related to intermittent claudication, arteriosclerosis obliterans, diabetic arteriosclerosis, Raynaud's disease, angina pectoris, and sickle cell anemia .
loading...
    loading...
Cat. No.: HY-19091
CAS No.: 123297-52-9
ICI-170777 is an orally active cardiotonic agent and type III Phosphodiesterase inhibitor, with an IC50 of 2.5 μM against cyclic AMP phosphodiesterase type III from canine cardiac fractions. ICI-170777 inhibits Aldrin epoxidase and pentobarbital metabolism. It enhances β-adrenergic receptor-mediated positive inotropic effects without causing chronotropic effects, while also exerting balanced arteriolar/venular vasodilator, platelet aggregation inhibitor and smooth muscle relaxant activities. ICI-170777 restores cardiac function in an acute canine heart failure model, exhibits additive effects when combined with Ouabain (HY-B1457), and shows no significant activity against multiple receptor classes or non-cardiac systems. ICI-170777 can be used in research related to congestive heart failure .
loading...
    loading...